Pharmaceutical composition and method of treatment
OwnerHector C. Simoninventor
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition and method of treatment is provided for aiding the regression and palliation of cancers selected from the group consisting of leukemia, Ewing's sarcoma, stomach diffuse carcinoma, vesical adeno-carcinoma, lymphosarcoma, uterine cancer and lung cancer in humans which comprises the administration of a therepeutically effective amount of the said composition comprising friendelan-3-one contained in a physiologically acceptable solution.
Claims5
A method of aiding the regression and palliation of cancer selected from the group consisting of leukemia, Ewing's sarcoma, stomach diffuse carcinoma, vesical adeno-carcinoma, lymphosarcoma, uterine cancer and lung cancer in humans which comprises administering orally to an affected human a physiologically acceptable solution containing an amount of friedelan-3-one therapeutically effective to aid in the regression and palliation of said cancer.
A method for aiding the regression and palliation of cancer selected from the group consisting of leukemia, Ewing's sarcoma, stomach diffuse carcinoma, vesical adeno-carcinoma, lymphosarcoma, uterine cancer and lung cancer in humans which comprises administering orally to an affected human a solution containing about 0.01% to 0.4% by weight of friedelan-3-one dissolved in ethanol, said solution being administered at regular intervals on a daily basis in dosage amounts diluted in a beverage to enable the oral ingestion of said solution therapeutically effective to aid in the regression and palliation of said cancer.
A method for aiding the regression and palliation of cancer selected from the group consisting of leukemia, Ewing's sarcoma, stomach diffuse carcinoma, vesical adeno-carcinoma, lymphosarcoma, uterine cancer and lung cancer in humans which comprises orally administering to an affected human a solution containing about 0.01% to 0.4% by weight of friedelan-3-one dissolved in ethanol, said solution being administered at regular intervals on a daily basis in dosage amounts corresponding to about 2 to 60 .mu.g of friedelan-3-one diluted in a beverage to enable the oral ingestion of said solution.
Dependencies are inferred from the claim text.